Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Role of Brain Metastases and Quality of Life in Treatment Decisionmaking

June 12th 2023

Virginia Kaklamani, MD, DSc, shares her perspective on the roles that brain metastases and quality of life play, respectively, in selecting treatment for HER2+ mBC.

Factors in Selecting Third-Line Therapy for HER2+ Metastatic Breast Cancer

June 12th 2023

Focused discussion on factors that help inform treatment selection for patients with HER2+ metastatic breast cancer in the third-line setting.

Dr Partridge on Breast Cancer Recurrence in Young Breast Cancer Survivors

June 9th 2023

Ann H. Partridge, MD, MPH, discusses the incidence of second primary breast cancer in young patients with a history of breast cancer.

Dr Waks on Survival Outcomes With Chemotherapy in Small Node-Negative HER2+ Breast Cancer

June 9th 2023

Adrienne G. Waks, MD, discusses breast cancer survival in patients with small node-negative HER2-positive breast cancer according to the treatment modality received.

Dr Hamilton on the Efficacy and Safety of Abemaciclib Plus ET in Elderly Patients With HR+/HER2- Breast Cancer

June 8th 2023

Erika P. Hamilton, MD, discusses the efficacy and safety of adjuvant abemaciclib plus endocrine therapy in patients with hormone receptor–positive, HER2-negative, high-risk early breast cancer according to age.

Dr Bardia on Results of the NATALEE Trial in HR+/HER2– Early Breast Cancer

June 7th 2023

Aditya Bardia, MD, MPH, discusses the investigation of ribociclib and endocrine therapy vs endocrine therapy alone as adjuvant treatment in patients with hormone receptor-positive/HER2-negative early breast cancer, highlighting primary results from the phase 3 NATALEE trial.

Dr Tolaney on Final OS Data From the TROPiCS-02 Trial in HR+/HER2- Breast Cancer

June 7th 2023

Sara M. Tolaney, MD, MPH, discusses key data from a final overall survival analysis of the phase 3 TROPiCS-02 trial in hormone receptor–positive, HER2-negative breast cancer.

Breaking Down the Data in Genitourinary, Gastrointestinal, and Breast Cancers, Plus Sarcoma and Melanoma at ASCO 2023: Drs Rini, Lewis, Trent, Luke, Kunz, and Lustberg

June 6th 2023

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across hematologic oncology during the conference.

Sacituzumab Govitecan Displays OS Benefit in Pretreated HR+/HER2– Breast Cancer

June 6th 2023

Sacituzumab govitecan demonstrated an overall survival benefit vs physician's choice of treatment in patient with pretreated, endocrine-resistant, hormone receptor–positive, HER2-negative metastatic breast cancer.

HER3-DXd Elicits Responses and Safety in Heavily Pretreated ER+ Breast Cancer and TNBC

June 5th 2023

Patritumab deruxtecan displayed manageable safety and produced responses in heavily pretreated patients with estrogen receptor–positive or triple-negative metastatic breast cancer with varying levels of HER3 expression, according to data from a phase 2 study presented at the 2023 ASCO Annual Meeting.

Overview of the HER2+ Metastatic Breast Cancer Treatment Armamentarium

June 5th 2023

A key opinion leader in breast cancer management shares insight on the treatment armamentarium for patients with HER2+ disease.

Patient Profile: A 68-Year-Old Woman With HER2+ Metastatic Breast Cancer

June 5th 2023

Expert oncologist Virginia Kaklamani, MD, DSc, shares her perspectives on a patient case of HER2+ metastatic breast cancer (mBC) treated with multiple lines of therapy.

Zotatifin Triplet Shows Promising Activity, Low Toxicity in Heavily Pretreated ER+ Breast Cancer

June 5th 2023

The triplet combination of zotatifin, abemaciclib, and fulvestrant demonstrated a confirmed overall response rate of 21% in heavily pretreated patients with estrogen receptor–positive metastatic breast cancer.

Subgroup Analysis Demonstrates Promising Activity With Elacestrant in ER+/HER2- Advanced or Metastatic Breast Cancer

June 4th 2023

Findings from a subgroup analysis of the phase 3 EMERALD trial presented during the 2023 ASCO Annual Meeting demonstrated elacestrant elicited prolonged progression-free survival compared with standard-of-care therapy for patients with estrogen receptor-positive, HER2-negative non-detected ESR1 mutated breast cancer who experienced disease progression within 6 months of CDK4/6 inhibitor treatment plus endocrine therapy.

Efficacy and Safety of Abemaciclib Plus ET Is Maintained Older Patients with HR+, HER2–, Early Breast Cancer

June 3rd 2023

A clinically meaningful absolute risk reduction in invasive disease-free survival and distant relapse-free survival with abemaciclib plus endocrine therapy was maintained in patients with hormone receptor–positive, HER2-negative, high-risk early breast cancer regardless of age.

Dr Champ on the Consideration of Using Radiation Therapy in Breast Cancer

June 2nd 2023

Colin E. Champ, MD, discusses the importance of considering the use of radiation therapy for patients with breast cancer and details ongoing research into this arena.

Addition of Ribociclib to Endocrine Therapy Provides iDFS Benefit in HR+/HER2– Early Breast Cancer

June 2nd 2023

Treatment with ribociclib plus endocrine therapy led to a statistically and clinically meaningful improvement in invasive disease-free survival among patients with hormone receptor–positive/HER2-negative early breast cancer compared with endocrine therapy alone, meeting the primary end point of the phase 3 NATALEE trial.

Dr Yuan on the Importance of Clinical Trial Enrollment in Breast Cancer

June 1st 2023

Yuan Yuan, MD, PhD, discusses the importance of clinical trial participation and enrollment in patients with breast cancer.

HER3+ CTC Count May Affect Responses to Patritumab Deruxtecan in Pretreated Advanced Breast Cancer

June 1st 2023

Higher baseline HER3-positive circulating tumor cell count at baseline and reduction following treatment initiation was associated with a higher likelihood of deriving an early response with patritumab deruxtecan in patients with hormone receptor–positive or HER2-low advanced breast cancer.

ASCO 2023 Insights: ADCS, Next-Generation TKIs, and More Lead Data Pack Ahead of Annual Meeting

May 31st 2023

Experts in the field share the abstracts they found to be the most practice changing at this year’s ASCO Annual meeting.